Takeda Pharmaceutical Company Ltd
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone
- Conditions
- Hodgkin Lymphoma
- Interventions
- Other: No Intervention
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Takeda
- Registration Number
- NCT06104878
- Locations
- 🇧🇷
Oncoclinicas Rio de Janeiro S.A, Rio de Janeiro, Brazil
🇧🇷AC Camargo Cancer Center / Fundação Antonio Prudente Liberdade, Sao Paulo, Brazil
🇧🇷Beneficência Portuguesa de São Paulo - Real Benemerita Associação Portuguesa de Beneficência, Sao Paulo, Brazil
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- Conditions
- Crohn's DiseaseUlcerative Colitis
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 70
- Registration Number
- NCT06100289
- Locations
- 🇪🇸
Hospital Arquitecto Marcide de Ferrol, Ferrol, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Universidad de Sevilla - Hospital Universitario Virgen Macarena, Sevilla, Spain
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 65
- Registration Number
- NCT06095128
- Locations
- 🇺🇸
Digestive Health Specialsits, Dothan, Alabama, United States
🇺🇸GI Alliance Sun City, Sun City, Arizona, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 693
- Registration Number
- NCT06088043
- Locations
- 🇺🇸
Saguaro Dermatology Associates, LLC - Probity - PPDS, Phoenix, Arizona, United States
🇺🇸First OC Dermatology - Fountain Valley, Fountain Valley, California, United States
🇺🇸Center for Dermatology Clinical Research, Fremont, California, United States
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- Device: SC Investigational Needle Sets
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 39
- Registration Number
- NCT06076642
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
🇺🇸Duke Asthma, Allergy and Airway Center, Durham, North Carolina, United States
🇺🇸Allergy Partners of North Texas, Dallas, Texas, United States
A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India
- Conditions
- Healthy Volunteers
- Interventions
- Biological: TDVBiological: Placebo
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 480
- Registration Number
- NCT06060067
- Locations
- 🇮🇳
BGS Global Institute of Medical Sciences (BGS-GIMS) #67, BGS Health & Education City, Uttarahalli Main Road, Kengeri, Bangalore, Karnataka, India
🇮🇳Preventive and Therapeutic Clinical Trial Unit (PTCTU), Dept. of Community Medicine, Institute of Medical Science and SUM Hospital, K-8, Kalinga Nagar, Bhubaneshwar, India
🇮🇳SRM Medical College Hospital & Research Centre, SRM Nagar, Potheri, Kattankulathur, India
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 150
- Registration Number
- NCT06045754
- Locations
- 🇺🇸
GI Alliance Sun City, Sun City, Arizona, United States
🇺🇸University of California San Diego Health (UCSD), La Jolla, California, United States
🇺🇸Digestive Health Specialsits, Dothan, Alabama, United States
Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment
- Conditions
- Hunter Syndrome
- Interventions
- Drug: Idursulfase-IT
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 6
- Registration Number
- NCT06031259
- Locations
- 🇨🇦
M.A.G.I.C. Clinic, Calgary, Alberta, Canada
🇨🇦University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦Hospital for Sick Children, Toronto, Ontario, Canada
A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 172
- Registration Number
- NCT05995249
- Locations
- 🇺🇸
Celerion - Tempe, AZ Site, Tempe, Arizona, United States
A Study of TAK-279 in Adults With or Without Kidney Problems
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 24
- Registration Number
- NCT05992155
- Locations
- 🇺🇸
Research by Design, Chicago, Illinois, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States